Improving tuberculosis treatment with better drug monitoring in low-resource areas
Improving the effectiveness of anti-tuberculosis drugs by developing a point-of-care therapeutic drug monitoring system for areas with limited medical resources
This study is working on a new way to help people with tuberculosis get the right amount of medicine they need, especially for those who also have HIV or diabetes, by using a simple system to check their drug levels without needing fancy lab equipment.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glucosentient, INC. NIH-funded |
| Lab location | 1 site (Champaign, United States) |
| Project ID | NIH-10820806 on NIH RePORTER |
What this research studies
This research aims to enhance the effectiveness of tuberculosis (TB) treatment by developing a point-of-care therapeutic drug monitoring system. The approach focuses on ensuring that patients receive adequate drug exposure, which is crucial for successful treatment, especially in areas with limited medical resources. By measuring drug levels in the blood, the system will help prevent treatment failures and drug resistance, particularly for individuals co-infected with HIV or diabetes. The methodology involves creating a more accessible and efficient way to monitor drug levels without relying on expensive laboratory equipment.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with tuberculosis, especially those living in low-resource settings or co-infected with HIV or diabetes.
Not a fit: Patients who are not diagnosed with tuberculosis or those living in well-resourced healthcare environments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve TB treatment outcomes and reduce the incidence of drug-resistant TB.
How similar studies have performed: Previous research has shown that effective therapeutic drug monitoring can improve treatment outcomes for TB, indicating that this approach has potential for success.
Where this research is happening
Champaign, United States
- Glucosentient, INC. — Champaign, United States (Active)
Researchers
- Principal investigator: Lan, Tian — Glucosentient, INC.
- Study coordinator: Lan, Tian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.